IP Library Granted Patent US 7,683,056
Granted Patent B2
US 7,683,056 · App. 12/065,923 · Granted Mar 23, 2010

Pyridine derivatives and their use in the treatment of psychotic disorders

Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,683,056
App. No.
12/065,923
Granted
Mar 23, 2010
Kind
B2
Abstract

There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein all variables are defined herein. Also provided are pharmaceutical compositions containing the same and methods for their use in therapy.

Claims (13)

1. A compound of formula

or a pharmaceutically acceptable salt thereof.

2. 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide.

3. 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide hydrochloride.

4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

5. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier or excipient.

6. A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier or excipient.

7. A method of treatment of a Depressive Disorder or schizophrenia which comprises administering to a human in need thereof an effective amount of a compound according to claim 1 .

8. A method of treatment of a Depressive Disorder or schizophrenia which comprises administering to a human in need thereof an effective amount of a compound according to claim 2 .

9. A method of treatment of a Major Depressive Disorder which comprises administering to a human in need thereof an effective amount of a compound according to claim 1 .

10. A method of treatment of a Major Depressive Disorder which comprises administering to a human in need thereof an effective amount of a compound according to claim 2 .

11. A method of treatment of schizophrenia which comprises administering to a human in need thereof an effective amount of a compound according to claim 1 .

12. A method of treatment of schizophrenia which comprises administering to a human in need thereof an effective amount of a compound according to claim 2 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: NERRE THERAPEUTICS LIMITED
To: KANDY THERAPEUTICS LIMITED
Reel/Frame 054687/0378 →
CHANGE OF ADDRESS Recorded Dec 9, 2020
From: NERRE THERAPEUTICS LIMITED
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 054663/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2013
From: GLAXOSMITHKLINE LLC
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 029794/0242 →
CHANGE OF NAME Recorded Dec 17, 2009
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023667/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2008
From: ALVARO, GIUSEPPE; ANDREOTTI, DANIELE; BELVEDERE, SANDRO; DI FABIO, ROMANO; FALCHI, ALESSANDRO; GIOVANINNI, RICCARDO
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 020899/0580 →
Priority Claims (2)
GB 0518472.6 · Sep 9, 2005 · national
GB 0611153.8 · Jun 6, 2006 · national
Continuity (1)
Related Publication 20080269208A1 · Oct 30, 2008